UCB SA (UCB.BR): the Belgian pharma stock explained

2026-06-23 · By Lubin Danilo, founder of Lubin Investment

UCB SA is a Belgian biopharmaceutical company founded in 1928, listed in Brussels, running two global franchises: neurology (epilepsy) and immunology (psoriasis, bone diseases). Its free cash flow per share has grown 43% a year on average over five years, its balance sheet carries zero net debt, and it has raised its dividend for 25 consecutive years. It is a quiet cash machine, well under the radar of most English-speaking investors.

• UCB SA is a Belgian pharma focused on neurology (Briviact, Vimpat for epilepsy) and immunology (Bimzelx for psoriasis, Evenity for bone diseases).
• Its free cash flow per share has grown 43.4% a year over five years: exceptional even by global pharma standards.
• The balance sheet is net cash: zero net debt, debt-to-FCF ratio of 0.0. The company could repay everything tomorrow.
• 25 consecutive years of dividend growth, a sign of rare management discipline.
• The stock trades at 27.5 times its free cash flow, a premium multiple justified by the quality of its growth profile.

Who is UCB SA?

UCB SA does not make headlines in most financial media, and that is precisely what makes it interesting to me. Founded in Brussels in 1928, it spent decades concentrating all its energy on two fields: central nervous system diseases and immune system diseases. The result: it now ranks among the global leaders on both fronts, with a market capitalisation of around 56 billion dollars.

Its drug portfolio is readable: Briviact and Vimpat for epilepsy, Bimzelx (bimekizumab) approved for plaque psoriasis and expanding towards other indications, and Evenity for bone diseases like osteoporosis. These are not accidental blockbusters: each one addresses an unmet medical need in a market where UCB has built expertise that is hard to copy.

Why free cash flow is the real thermometer

Before going further, a word on free cash flow, because it is the measure I use everywhere. Free cash flow is the money that truly stays in the bank after paying everything needed to run and invest in the company: wages, factories, machines, taxes. It is harder to dress up than accounting profit, so I trust it more.

At UCB, the free cash flow margin reaches 23.8%. That means for every 100 euros of sales, 23.80 euros end up as genuinely available cash. That is already very solid in pharma. But what really stopped me was the FCF per share CAGR over five years: 43.4% a year. That is exceptional, even in a sector where margins are generally high.

UCB SA key metrics

The 10/10 score and Cash ROCE: what they mean

I score every company against 10 fundamental quality criteria: profitability, growth in sales and cash, conversion of accounting profit into real cash, balance sheet strength, return on capital, shareholder policy. A company that passes everything gets 10 out of 10. UCB gets the maximum score. That is not common.

Cash ROCE (cash return on capital employed) answers a simple question: for every euro invested in the business, how much cash does it return each year? At UCB, the answer is 28.0 cents per euro per year. That is well above the threshold I consider excellent. In plain terms, every euro of capital works hard, and management does not waste shareholders' money.

UCB's moat: what protects the franchise

A moat is a company's competitive trench: what stops a rival from taking its place. In specialised pharma, that trench has three components. First, intellectual property: patents giving UCB exclusivity on its molecules for years. Second, regulatory barriers: getting FDA or EMA approval for an indication takes a decade and billions of euros. Third, clinical expertise: UCB has built data and relationships with specialist physicians in neurology and immunology that no one can copy in a few years.

Bimzelx illustrates this dynamic well. Bimekizumab inhibits both IL-17A and IL-17F, two molecules involved in inflammation. That is a different approach from IL-17A-only inhibitors (like a competitor's secukinumab). Clinical studies show superior skin clearance in plaque psoriasis. UCB is now expanding indications to psoriatic arthritis, ankylosing spondylitis, and other inflammatory diseases. Each new indication opens a new market without having to reinvent the molecule.

The valuation: what 27.5 times free cash flow buys

To measure what the market is willing to pay, I use the P/FCF (price to free cash flow): the share price divided by the free cash flow generated per share each year. A P/FCF of 27.5 means you are paying today the equivalent of 27.5 years of that cash. That is a demanding valuation, and I will be honest about that.

But here is the context: when free cash flow per share grows 43% a year, a P/FCF of 27.5 is digested much faster than it looks. If that growth continues at even half that pace, the cash doubles in three to four years. This kind of profile justifies a premium, as long as the quality holds. And so far, it holds.

The dividend: 25 consecutive years of growth

The dividend yield is modest: 0.6% a year. This is not an income stock in the traditional sense. But what matters to me is consistency: 25 consecutive years of dividend increases. That means UCB has raised its dividend every year since 2001, through recessions, financial crises, and a pandemic. That is a strong signal about the quality of management and the robustness of cash flows.

Risks not to forget

Specialised pharma is not risk-free. The main one: patent dependency. When a patent expires, generics arrive and the price collapses. UCB must continuously fill its pipeline to offset future losses. Second risk: clinical trials fail. Even a promising candidate may not get regulatory approval, or may be approved for a narrower indication than expected. Third risk: competition. In the psoriasis market in particular, IL-17 and IL-23 inhibitors are multiplying. UCB must prove that Bimzelx is clinically superior, not just competitive.

Finally, valuation risk. A P/FCF of 27.5 leaves little margin for error. If growth slows significantly, or if a major clinical trial disappoints, the market can reprice the stock quickly. The business quality is real, but the price is demanding. I judge both separately, and I know the current price does not leave much cushion.

In short

UCB SA is a top-tier Belgian biopharmaceutical: net cash balance sheet, 25 years of rising dividends, free cash flow per share growing 43% a year, Cash ROCE of 28%, 10/10 score on my screener. The stock trades at 27.5 times its cash, which is demanding but reflects a rare growth profile. It is a company I watch closely, and the full analysis is available on the UCB.BR page of my site.

FAQ

What is the P/FCF and why use it for UCB?

The P/FCF (price to free cash flow) divides the share price by the free cash flow generated per share each year. It is more reliable than the P/E because free cash flow is harder to dress up than accounting profit. For UCB, it comes in at 27.5: you are paying 27.5 years of current cash. That is high, but justified by FCF per share growth of 43% a year.

What is Cash ROCE and why is 28% exceptional?

Cash ROCE measures the cash generated each year per euro of capital employed in the business. At 28%, UCB returns 28 cents of cash per euro invested per year. That is two to three times the threshold I consider excellent, a sign that management allocates capital efficiently.

Is UCB really a biotechnology company?

The screener classifies it as biotechnology, but in reality UCB is a specialised biopharmaceutical: it develops, manufactures, and commercialises its own approved drugs, with stable and recurring revenues. It is not a pure clinical-stage biotech with no revenue.

Why is the dividend so low (0.6%) if the company is so profitable?

UCB reinvests a large portion of its cash into R&D and the clinical expansion of Bimzelx. The low yield reflects a strategic choice: create value through growth rather than distribution. The 25 consecutive years of dividend increases show the strength of cash flows, not their absence.

Where can I find the full UCB.BR analysis?

The detailed analysis with all criteria, sector comparables and scoring breakdown is available on the /analyse/UCB.BR page of Lubin Investment. This article is an introduction, not investment advice.

Voir l'analyse UCB.BR sur Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I have analyzed stocks through their fundamentals for several years and invest my own money with this method. I codified it into a tool that judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).